title: Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone.
abstract: OBJECTIVE
  To evaluate the effect of patient age on intraocular pressure (IOP) response after intravitreal injection of triamcinolone acetonide (IVTA).
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  A total of 164 outpatients (164 eyes) aged 21 to 80 years (mean, 56.8 years), presenting with exudative age-related maculopathy (51) or macular edema of various etiologies (113), received IVTA (4 mg/0.1 ml). The primary outcome measure was IOP elevation >21 mm Hg. Patients were re-evaluated at one week, and one, three, and six months.
  
  
  RESULTS
  The mean baseline IOP was 15.07 mm Hg; the mean rise was 6.6 mm Hg. IOP >21 mm Hg was observed in 42 (25.6%) patients. In the age group </=45 years, IOP rise occurred in 45% (14/31) patients, compared with 21% (28/133) of older patients (P = .006). The groups were similar in baseline IOP, IOP rise, mean time-lag to maximum IOP, and response to treatment.
  
  
  CONCLUSIONS
  IVTA caused more frequent IOP elevation in younger patients; other aspects of IOP response and its treatment were similar to older patients.
authors.affiliation: Aravind Eye Hospital & Postgraduate Institute of Ophthalmology, Madurai, Tamil Nadu, India. daksh66@gmail.com
authors.forename: Dhananjay
authors.initials: D
authors.lastname: Shukla
authors.forename: Nagasubramaniam
authors.initials: N
authors.lastname: Vidhya
authors.forename: Noela M
authors.initials: NM
authors.lastname: Prasad
authors.forename: Rajendran
authors.initials: R
authors.lastname: Mahalakshmi
authors.forename: Chandarmohan
authors.initials: C
authors.lastname: Kolluru
authors.forename: Ramaswami
authors.initials: R
authors.lastname: Krishnadas
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced*; D011446:Prospective Studies; D012307:Risk Factors; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide